Nanomedicine
Oncotelic Therapeutics Featured in Editorial on Nanomedicine Advances in Oncology
Oncotelic Therapeutics' inclusion in a NetworkNewsWire editorial highlights how its Deciparticle platform represents significant progress in nanomedicine for improving cancer drug delivery and reducing toxicity.
Nanomedicine Breakthroughs Reshape Cancer Treatment Through Enhanced Drug Delivery
Advances in nanomedicine delivery systems are addressing critical limitations in cancer therapy by improving drug bioavailability and targeting while reducing toxicity, potentially transforming treatment standards across the oncology landscape.
Oncotelic Therapeutics Advances RNA-Based and Immunotherapy Pipeline to Address Unmet Medical Needs in Cancer and Rare Diseases
Oncotelic Therapeutics is leveraging AI and nanomedicine to develop breakthrough treatments for aggressive cancers and pediatric rare diseases, positioning the company alongside industry leaders in transforming biotech innovation.
NanoViricides to Present at D. Boral Capital Inaugural Global Conference, Highlighting Antiviral Drug Development
NanoViricides, a clinical-stage biotech company specializing in nanomedicine-based antiviral treatments, will participate in the D. Boral Capital Inaugural Global Conference, offering investors insights into its advanced drug candidates targeting respiratory viral infections and other diseases.